| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-07-0403 |
| P698 | PubMed publication ID | 17671130 |
| P50 | author | Daniel Sterman | Q49967205 |
| Carl H. June | Q19277113 | ||
| P2093 | author name string | Ira Pastan | |
| Richard G Carroll | |||
| Jing Sun | |||
| Mitchell Ho | |||
| Robert H Vonderheide | |||
| Anil Vachani | |||
| Steven M Albelda | |||
| Daniel F Heitjan | |||
| Jennifer L Brown | |||
| Veena Kapoor | |||
| Xin-qiao Zhang | |||
| Larry R Kaiser | |||
| Michael Parr | |||
| Leslie A Litzky | |||
| Andrew Haas | |||
| Michael Machuzak | |||
| Elaina M Lord | |||
| Michelle Kanther | |||
| Adri Recio | |||
| Colin T Gillespie | |||
| Richard Hodinka | |||
| William Benedict | |||
| Michael J Corbley | |||
| P433 | issue | 15 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| malignant pleural mesothelioma | Q18557602 | ||
| P304 | page(s) | 4456-4466 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses | |
| P478 | volume | 13 |
| Q34747045 | 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy |
| Q41846143 | A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine |
| Q24658397 | A binding domain on mesothelin for CA125/MUC16 |
| Q35855798 | A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. |
| Q39916361 | A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells |
| Q39771175 | A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. |
| Q33523445 | A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions |
| Q33923147 | A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q37549196 | Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer |
| Q45886686 | Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis |
| Q33759287 | B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis |
| Q37785836 | Cancer Immunotherapy and Nanomedicine |
| Q34343736 | Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms |
| Q37863562 | Chemotherapy and Radiotherapy for Mesothelioma |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q51434808 | Current best practice in the evaluation and management of malignant pleural effusions |
| Q37817035 | Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment |
| Q37400550 | Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity |
| Q37065997 | Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches. |
| Q33691838 | Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy |
| Q39796367 | Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma |
| Q38473933 | Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor |
| Q82353451 | Gene Therapy for Lung Neoplasms |
| Q37868973 | Gene Therapy for Mesothelioma |
| Q39511773 | Gene therapy for lung cancer malignant pleural effusion: current and future nano-biotechnology |
| Q38079969 | Gene therapy for malignant mesothelioma: Current prospects and challenges |
| Q37693512 | Gene therapy for mesothelioma and lung cancer |
| Q39778480 | Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta |
| Q47862061 | Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma. |
| Q36711060 | Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes |
| Q35711576 | Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma |
| Q28390399 | Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients |
| Q39351008 | Immunotherapy for malignant mesothelioma: Reality check |
| Q38180749 | Immunotherapy for malignant pleural mesothelioma. Current status and future prospects |
| Q34974037 | Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells |
| Q38221769 | Interventional therapies for malignant pleural effusions: the present and the future. |
| Q37408325 | Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model |
| Q39457393 | Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses |
| Q34293068 | Investigational Approaches for Mesothelioma |
| Q44173242 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q92586096 | Making cold malignant pleural effusions hot: driving novel immunotherapies |
| Q91026388 | Malignant pleural effusion management: keeping the flood gates shut |
| Q83412919 | Malignant pleural mesothelioma |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q38022486 | Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. |
| Q35042668 | New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials |
| Q37360580 | New diagnostic and molecular characteristics of malignant mesothelioma |
| Q39067827 | Novel oncolytic viral therapies in patients with thoracic malignancies |
| Q40051845 | Oncolytic Viral Therapy for Mesothelioma |
| Q24605512 | Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy |
| Q26826590 | Oncolytic virotherapy for human malignant mesothelioma: recent advances |
| Q39643717 | Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma |
| Q82235520 | Peritoneal mesothelioma |
| Q52650848 | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion |
| Q38416306 | Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy |
| Q83253835 | Pleural Diseases in the Molecular Era – Time for More Answers: Introduction |
| Q37777879 | Pleural Malignancies |
| Q39415827 | Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. |
| Q35175013 | Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma |
| Q39359156 | SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma |
| Q33556564 | Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines |
| Q89390949 | Scientific Advances and New Frontiers in Mesothelioma Therapeutics |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q37347017 | Suicide Gene Therapy for Cancer - Current Strategies |
| Q37087603 | Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy |
| Q89907253 | The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin |
| Q35058213 | The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. |
| Q55279228 | The role of intracavitary therapies in the treatment of malignant pleural mesothelioma. |
| Q36907325 | The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion |
| Q40002363 | Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion |
| Q48355318 | Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. |
| Q35876239 | Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity |
| Q38128561 | Update on oncolytic viral therapy - targeting angiogenesis |
| Q39775324 | Using lentiviral vectors for efficient pancreatic cancer gene therapy |
| Q52769268 | Viroimmunotherapy of Thoracic Cancers |
| Q33781142 | What's the place of immunotherapy in malignant mesothelioma treatments? |
Search more.